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SUMMARY
The association between small but still visible lacunar infarcts and cognitive decline has been
established by multiple population-based radiological and pathological studies. Microscopic
examination of brain sections reveals even smaller but substantially more numerous microinfarcts,
the focus of the current review. These lesions often result from small vessel pathologies such as
arteriolosclerosis or cerebral amyloid angiopathy. They typically go undetected in clinical-
radiological correlation studies that rely on conventional structural MRI, though the largest acute
microinfarcts may be detectable by diffusion-weighted imaging. Given their high numbers and
widespread distribution, microinfarcts may directly disrupt important cognitive networks and thus
account for some of the neurologic dysfunction seen in association with lesions visible on
conventional MRI such as lacunar infarcts and white matter hyperintensities. Standardized
neuropathological assessment criteria and development of non-invasive means of detection during
life would be major steps towards understanding the causes and consequences of the otherwise
macroscopically invisible microinfarct.
© 2012 Elsevier Ltd. All rights reserved.
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INTRODUCTION
Many neuropathology and neuroimaging studies have shown that asymptomatic
cerebrovascular disease is extremely common.. Further, this so-called “silent” pathology
accounts for a surprisingly high portion of dementia.1 Lacunes and white matter lesions
(WMLs) in particular have emerged as clear-cut risk factors for dementia in multiple
population-based clinical-radiological studies.2, 3
While the association between these visible manifestations of cerebral small vessel disease
is strong and consistent, the mechanism remains challenging to explain. Are one or two
lacunes, for example, truly sufficient to impair cognition as suggested epidemiologically?
An important alternative explanation is that those few readily detectable lesions are instead
markers for substantially more numerous and widespread infarcts that are not visible to the
naked eye. Tiny microinfarcts are indeed a well described neuropathologic finding. These
lesions are characterized by bona fide tissue infarction, but on a scale that renders them
unapparent on gross pathologic examination or conventional structural MR imaging. This
review synthesizes current knowledge of the detection, appearance, prevalence, distribution,
and functional impact of microinfarcts along with recommended areas for future
investigation. Although microinfarcts represent just one in a spectrum of small vessel-
associated forms of brain injury (a list that also includes white matter T2-hyperintense
lesions and cerebral microbleeds), current data suggest that they may comprise the single
most widespread form of brain infarction and thus a major component of the causal pathway
between cerebral small disease and cognitive dysfunction.
SEARCH STRATEGY AND SELECTION CRITERIA
The PubMed database was searched with the Ovid search engine on December 2 2011 using
the terms “microinfarct(s)” and “microscopic infarct(s)” as keywords and MeSH headings,
and limited to articles including “brain”, “cerebral” or “central nervous system” as keywords
or MeSH headings. The search yielded 535 articles. A single author (EES) screened the
abstracts and eliminated 438 articles as not relevant; all study authors reviewed the
remaining 97 articles. Another 27 relevant articles were identified by consultation with
experts and hand searching of the reference lists of the retrieved articles.
STATISTICAL ANALYSIS
To derive the univariate pooled odds ratio for the relationship between microinfarcts and
dementia, we abstracted information on the prevalence of microinfarcts in persons with and
without dementia from the studies selected for review (see “Search Strategy and Selection
Criteria”). To reduce the risk of bias we only pooled data from community-based studies of
all-cause mortality that prospective selected participants during life, without including
hospital or clinic-based studies, for example. Univariate odds ratios were graphically
displayed as a forest plot and a pooled odds ratio was calculated using the DerSimonian and
Laird random effects model.4 Heterogeneity in the odds ratios across studies was quantified
by the I-squared measure5 and tested using the chi-square test. Statistical analyses were done
using Stata version 9.2 (StataCorp, Texas, USA).
NEUROPATHOLOGY OF MICROINFARCTS
Cerebral microinfarcts are typically defined as sharply delimited microscopic regions of
cellular death or tissue necrosis, sometimes with cavitation (that is, a central fluid-filled
cavity). The term “microscopic” denotes that these lesions are not visible by gross
inspection of the brain but seen by light microscopy (Figure 1).6–9 The term “infarct” is
most commonly used for ischemia-related tissue loss, and indeed the pathologic appearance
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of microinfarcts is consistent with that of known ischemic infarctions. The precise
pathophysiologic cause or causes of microinfarcts are not entirely defined, however. To be
consistent with prior literature, we will nonetheless continue to refer to these lesions as
“microinfarcts.”
There are surprisingly few guidelines for the identification of microinfarcts, and many
studies provide little information on inclusion or exclusion criteria. The National Institute of
Neurologic Disorders and Stroke – Canadian Stroke Network Vascular Cognitive
Impairment (NINDS-CSN VCI) Harmonization Standards6 uses the standard approach
defining microinfarcts as lesions “not visible to the naked eye but detected on histologic
examination” and further suggest that microinfarcts be differentiated from “incomplete
ischemic injury” or subinfarctive lesions, which appear as foci of cell loss or tissue
rarefaction with reactive changes but without frank tissue loss. However, this differentiation
can be difficult in practice. For example, a tissue section at the periphery of a genuine
microinfarct may demonstrate only subinfarctive changes, as cavitated infarcts can be
surrounded by gliosis some distance from their nidus.10 For this reason, some studies are
inclusive of these incompletely infarcted lesions and define microinfarcts to include foci of
tissue pallor or astrocytosis,8, 11, 12 whereas others require evidence of frank tissue necrosis
or encephalomalacia.7, 13, 14 Some studies further exclude infarcts that are over 2 mm14 or 4
mm12 in diameter; presumably to exclude lesions that should be grossly visible. Another
source of variability in microinfarct detection is staining method. Although most studies
suggest that microinfarcts are readily identified on routine hematoxylin and eosin (H&E)
stain,7, 11 immunohistochemical staining for markers of tissue injury such as reactive
astrocytes15 or activated microglia16 may make microinfarcts more recognizable and easier
to count.7 However, the sensitivity and specificity of different staining methods for
microinfarcts has not been rigorously studied.
When identified in early stages of their evolution, microinfarcts show the predicted acute
ischemic appearance of red neurons (if cortical) and loss of tinctorial staining quality,
sometimes with vacuolization from cytotoxic edema. In subacute stages (starting at 3 to 5
days post-infarct), the lesions demonstrate an influx of macrophages that often clearly
demarcate the central region of the infarct from surrounding tissue. At approximately 10
days this is followed by a surrounding gemistocytic astrocytosis and fading of the dying
neurons. Chronic lesions typically show cavitation with few remaining central macrophages
and a surrounding fibrillary gliosis. However, chronic microinfarcts can also appear as a
linear “scar” with acellularity and fibrillary gliosis but little or no cavitation, causing
invagination of the pial surface and puckering of the surrounding tissue when in the cortex,
or if numerous, creating a cortical appearance of “granular atrophy”.17 It is important to note
that like other foci of tissue necrosis, microinfarcts can have distant tissue effects such as
Wallerian, retrograde, or transynaptic degeneration.7 The combination of local peri-infarct
gliosis10 and distant degeneration may thus make the pathologic impact of microinfarcts
more widespread than simply the tissue volume occupied by the microinfarcts themselves.
Typical microinfarct size appears to be quite small. In a study of microscopic lesions
containing tissue necrosis, mean diameter of the lesions was approximately 0.2 mm.18 In
another community-based clinical-pathologic study of aging the average size was much
larger, 1mm, with a range of 0.2 to 2.9 mm.19 The small average size highlights the
challenges in designing imaging methods for detecting microinfarcts (see later
Neuroimaging of Cerebral Microinfarcts).
Microinfarcts are very common in the aging brain. Estimates of the frequency of one or
more detectable microinfarcts range from 16% to 46% in unselected elderly persons dying
of all causes (Table 1). Microinfarcts were detected in 33% of cognitively normal elderly
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dying of all causes in a combined analysis of 4 studies.20 The heterogeneity in observed
prevalence likely arises in part from differences in cohort characteristics such as age and
coexisting medical conditions. An additional source of variation is the sampling strategy.
Because microinfarcts are very small lesions within a large brain that is typically only
sparsely sampled for microscopic pathology, their prevalence is likely to be affected by both
the volume and location of examined tissue. Sampling strategy is not necessarily the
overriding determinant of microinfarct prevalence, however; for example, a frequency of
19.3% was reported with 38 regions sampled11 whereas another study found a frequency of
30% with only 9 regions sampled.21
Microinfarct burden is often expressed as the number of microinfarcts per number of blocks
from specific regions16 or by semiquantitative estimates across all sampled tissue blocks
(e.g. none, one, more than one or more than two).8, 14, 22 The numbers of microinfarcts
detected in these studies are likely vast underestimates of the total brain burden, however, as
even systematic tissue sampling methods examine only a tiny fraction of the overall brain
volume. Calculations based on the sampling protocol used in reference 21 indicate that
observation of 1 or 2 microinfarcts in sampled tissue suggests the likely presence of
hundreds of microinfarcts across the total brain volume (Schneider and Greenberg,
unpublished data). Although direct measurement of total brain microinfarct burden has not
been performed (and may indeed be impractical), these calculations suggest that true number
is almost certainly orders of magnitude greater than the total burden of grossly visible
lacunar infarcts (typically 1 to 15 per brain).23
Determining the distribution of microinfarcts across the brain, like their prevalence and
overall burden, is likely influenced by sampling strategy, which varies among studies. A
reasonable approach to standardized sampling is the Consortium to Establish a Registry for
Alzheimer’s Disease (CERAD) protocol for brain sampling with additional sectioning of the
anterior (centrum semiovale) and posterior white matter24 as suggested by the NINDS –
CSN VCI Harmonization Standards.6 Other important areas for sampling may include the
border zones of major arterial territories18, 25, 26 as well as brain regions commonly involved
by lacunar infarction, the basal ganglia, thalamus, pons and cerebellum.
Microinfarct location can be classified as cortical or subcortical, a distinction that may be
useful for identifying associations with specific diseases.. Some studies of AD, for example,
report cortical microinfarcts predominantly in brain arterial border zone areas18, 25, 26 or in
motor cortex in the setting of AD with motor impairment.27 Cortical microinfarcts have also
been associated with cerebral amyloid angiopathy (CAA),16, 26, 28–32 though the relationship
may be complicated by CAA-related perivascular hemosiderin deposition and astroglial
scarring that can be difficult to distinguish from incomplete microinfarction. Subcortical
microinfarcts, particularly in the putamen, have been described in hypertension33 and
hypertensive encephalopathy34, and are probably associated with arteriolosclerosis, whereas
periventricular microinfarcts have been described in normal pressure hydrocephalus.35
MICROINFARCTS AND SMALL VESSEL BRAIN DISEASE
In using the term “microinfarcts” for these lesions, the underlying supposition is that these
lesions are indeed the results of ischemic injury. Several lines of evidence support this
inference. As noted above, microinfarcts appear to share the histopathologic structure and
progression of macroscopic infarcts. Another suggestive feature is their association with
other markers of cerebrovascular disease such as ischemic macroscopic infarcts,
leukoencephalopathy, and intracerebral hemorrhages.7, 21, 36–38 Most notable are the
observed associations of microinfarcts with advanced small vessel diseases,14 including both
common age-related pathologies such as arteriolosclerosis and CAA16, 26, 28–32 and
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uncommon hereditary syndromes such as cerebral autosomal dominant arteriopathy with
subcortical infarcts and leukoencepalopathy (CADASIL).39, 40 Microinfarcts commonly
coexist with degenerative pathologies such as AD8, 9, 21, 37, 41 but the number of
microinfarcts does not appear to be related to the severity of AD pathology.19
Relatively few studies have systematically examined the relationship between microinfarcts
and vascular or other epidemiologic risk factors. Hypertension was identified as a risk factor
in two prospective cohort studies,37, 42 though not in another small study.43 When examined
in detail, the association between blood pressure and microinfarcts was seen in those under
age 80 but not those 80 and older, and was restricted to higher systolic but not diastolic
blood pressure readings.42 There is a reported association between cerebral microinfarcts
and history of coronary artery disease.37 Two studies have found associations between
microinfarcts and advanced age at death.36 The relationship with gender has been
inconsistent.36, 37
NEUROIMAGING OF CEREBRAL MICROINFARCTS
The autopsy-based studies discussed to this point are cross-sectional and therefore limited in
their ability to explore the incidence and consequences of microinfarcts. Therefore, there is a
need to identify microinfarcts during life in well-characterized clinical populations. The
major barrier to this goal is that microinfarcts are, by definition, invisible to the naked eye
pathologically and thus likely invisible to conventional structural MRI as well. This quality
puts microinfarcts in a distinct category from other features of cerebral small vessel disease
that are readily visible on conventional MRI, such as lacunar infarcts, white matter T2
hyperintensities (WMH), enlarged perivascular spaces, microbleeds, and atrophy.44
The paucity of clinical-imaging-pathological correlations45 means that it is difficult to be
certain whether some features or consequences of microinfarction might indeed be
detectable on structural MRI. Microinfarcts may, for example, contribute to the overall
appearance of WMH,46 but cannot easily be distinguished from the other pathologies that
contribute to this common MRI finding. It is notable that most imaging-pathological
comparisons of patients with small vessel disease to date have focused on periventricular
and deep white matter rather than cortical lesions,45, 47 whereas pathological studies of
microinfarcts have predominantly sampled the cortex. It is also possible that some of the
spherical or ovoid lesions described in recent studies as enlarged perivascular spaces (that is,
small CSF containing lesions visible in the white matter and basal ganglia on conventional
T2-weighted imaging)48–50 may actually be microinfarcts.
Given a mean diameter of 0.2 to 1 mm,18 the size of most microinfarcts is below the lower
limit of spatial resolution (approximately 1 mm3) for MRI at the conventional (1.5 or 3
Tesla) field strengths used in clinical practice. Lesions smaller than 1 mm will only be
visible if the lesional signal is strong enough to be detected despite partial volume averaging
with normal tissue also contained in the 1 mm3 voxel. Therefore, increased spatial resolution
will likely be needed for MRI to be able to detect individual microinfarcts and differentiate
them from other tiny lesions. Methods to increase the signal to noise ratio, such as higher
field strengths, might improve the visual contrast between microinfarction and normal tissue
and thus aid detection. A recent study using 7 Tesla post-mortem MRI, where multiple
lengthy acquisitions can be done and averaged to reduce noise, demonstrated infarcts in the
sub-millimeter range in a brain affected by CADASIL (Figure 2).51
During the acute phase, macroscopic infarcts can be sensitively52 (but imperfectly53)
detected by MRI diffusion-weighted imaging (DWI).54 Acute infarcts are visible as
hyperintense regions on DWI images or as hypointense regions on apparent diffusion
coefficient (ADC) images, reflecting decreased (restricted) diffusion of water protons in the
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infracted tissue. In acute infarction, water molecule diffusion decreases within minutes of
the onset of ischemia, then increases as barriers to diffusion, such as cellular membranes, are
broken down and scavenged.55–57 The rate of evolution is more rapid in gray matter than
white matter,58 and may be more rapid for smaller infarcts than larger infarcts and for milder
ischemic injuries than more severe. Lesions as small as 1 to 2 mm are detectable on MRI,
possibly somewhat enlarged from their pathological dimensions by the “blooming” effects
of the strong lesion signal.59 The size of the smallest infarcts detectable on DWI thus
approaches the boundary between what is pathologically considered a microinfarct versus a
macroscopic lacunar infarct. As the lesion evolves and ADC increases, the size of the lesion
may shrink and either cavitate, take on the appearance of WMH or even be indistinguishable
from normal tissue.60 There is thus only a relatively short time window (perhaps days) in
which a microinfarct might be DWI-detectable.
Despite these substantial temporal and spatial limitations, a surprisingly high rate of
incidental acute small infarction is detectable on DWI in patients with small vessel disease
such as CAA and CADASIL.61, 62 In a study of CAA patients, for example, DWI-positive
lesions were detected in 12 of 78 (15%) including 5 with 2 lesions (Figure 3).61 Based on
these data and a possibly generous estimated 10-day window in which the DWI lesions
might remain visible, the authors calculated that the average CAA patient may have 8
incident DWI-detectable small infarcts per year.61 Similarly, incidental small DWI-positive
lesions were detected in 16 to 19% of patients with acute lacunar stroke in 2 studies63, 64 and
13 to 31% of patients with acute intracerebral hemorrhage,65–67 with one study finding that
DWI-positive lesions were more frequent in the patients with CAA.66
The apparent association of incidental DWI-positive lesions with advanced small vessel
diseases as well as the absence of definite embolic sources in most cases68 support the
possibility that some of these lesions represent may acute microinfarction. However, it is not
known with certainty whether these DWI-positive neuroimaging lesions correspond
pathologically to acute microinfarcts, and direct DWI-pathological correlation therefore
remains an important goal for future investigation.
The brief time window for acute infarct detection by DWI imposes substantial limitations to
assessing the cumulative impact of ongoing acute small infarction. Detection of chronic
microinfarcts would be extremely useful, but faces technical challenges in spatial resolution
and in discrimination from other types of very small chronic lesions like focal WMH and
enlarged perivascular spaces.48–50 Possible approaches to improved microinfarct detection
are discussed below under Areas for Future Investigation.
MICROINFARCTS, COGNITIVE IMPAIRMENT, AND NEUROLOGIC
DYSFUNCTION
Data from the autopsy- and DWI-based studies described above suggest that though
individually small, microinfarcts may be quite numerous and thus capable of causing clinical
symptoms. The clinical syndrome most clearly related to microinfarction is cognitive
dysfunction.
Microinfarcts are frequently seen in autopsies of persons with vascular dementia or mixed
dementia.7, 28, 43, 69–73 However, determining whether microinfarcts contribute to the risk of
dementia is challenging, for two reasons. First, the frequency of microinfarcts is also
relatively high in brains of non-demented persons..72–74 Second, other vascular pathologies
—such as macroinfarcts, WMLs or CAA—are often seen along with microinfarcts in the
same brains. For these reasons, large samples including both demented and non-demented
Smith et al. Page 6
Lancet Neurol. Author manuscript; available in PMC 2013 March 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
persons with statistical modeling to control for the presence of other pathologies are needed
to determine the independent effect of microinfarcts on the risk of cognitive impairment..
A series of hospital-based autopsy studies from a single center suggests that microinfarcts
are indeed an independent predictor of cognitive dysfunction when simultaneously
accounting for other pathologies, including macroinfarcts. In these studies microinfarcts
were independently associated with increased odds of worse cognitive function in selected
populations with low75, 76 or high77 levels of neurofibrillary tangle pathology, and with76, 77
or without75 accompanying macroinfarcts (including lacunes). In their most inclusive cohort
containing all levels of neurofibrillary tangle pathology and macroscopic infarcts, the
cortical microinfarct score (range, 0–3) was independently associated with a 1.21-fold
increase in the odds of antemortem dementia per additional point on the score (95%
confidence interval 1.12–1.31, P<0.001).77 In patients with low or intermediate levels of
neurofibrillary tangle pathology (defined as Braak stage <III), cortical microinfarcts were
the single pathology that explained the most variation in Clinical Dementia Rating (CDR)
scale score even when simultaneously controlling for macroinfarcts and lacunes. 76, 78, 79
The authors suggested that cortical microinfarcts may make the clinical expression of
dementia more likely when there are intermediate levels of AD pathology present, as has
also been observed with macroscopic lacunar infarcts.80, 81 Limitations of these studies is
that cases were selected from a geriatric and psychiatric hospital and thus may not be
representative of the general population.
Most recently, the cognitive impact of microinfarcts has been investigated by several
autopsy studies based on prospective cohorts that are more representative of the community
than hospital- or clinic-based series. These studies recruited participants from the
community, including non-impaired persons, and prospectively followed them with
cognitive testing until death. After death, brain autopsies were conducted to identify the
neuropathologies associated with cognitive impairment or dementia (Table
1).8, 11, 19, 21, 27, 37, 82 The prevalence of microinfarcts ranged from 18% to 30% in 5 of the 7
studies. The other two studies reported higher prevalences of micoinfarcts (>40%); in one,
the mean age at death was relatively high (more than 90 years),82 while in the other, the
reasons for a higher prevalence of microinfarcts were unclear but could possibly be related
to the sampling strategy.8 Four of the 7 studies found a higher prevalence of microinfarcts in
persons with dementia compared to persons without dementia (30 to 64% versus 12 to
38%),8, 11, 37, 82 and 5 of the 7 studies found an independent association between
microinfarcts and dementia in multivariable-adjusted analyses.8, 11, 19, 37, 82 Microinfarcts
were not only common in clinically-diagnosed vascular dementia (18/25, 75%) or mixed
dementia (4/4, 100%) but also common in probable AD dementia (32/76, 44%).82 Pooling
the 7 studies, the prevalence of microinfarcts was nearly twice as high in persons who died
with dementia (280/488, 57%) than those who died without dementia (208/673, 31%)
(Figure 4).
In most cases microinfarcts co-exist with other pathologies, and are infrequently the sole
neuropathology in cognitively impaired persons. In two studies, only 13/118 (11%)11 and
3/179 (2%)22 of demented persons were found to have microinfarcts as the sole potential
cause of dementia. About half of patients with microinfarcts also had grossly visible
macroinfarcts, particularly lacunar infarcts; conversely, about half of patients with
macroinfarcts had accompanying microinfarcts.19, 22
To disentangle the relative contribution of these correlated pathologies—microinfarction and
macroinfarction—in the same set of brains, multivariable statistical modeling can be
employed. When controlling for the presence of larger infarcts including lacunes,
microinfarcts were independently associated with the risk of dementia in a series of single
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center hospital-based studies,75–77, 79 and in three prospective community-based
studies.11, 19, 37 In several of these studies larger infarcts were also associated with the risk
of dementia,19, 37, 76, 77 while in others only microinfarcts, but not larger infarcts, were
associated with dementia in the fully adjusted models. 11, 75, 79 In another study
microinfarcts, but not larger infarcts, were associated with dementia in univariate analysis.8
Conversely, only a single study found the opposite—that larger (macroscopic) infarcts, but
not microscopic infarcts, were associated with dementia in univariate and multivariable-
adjusted analyses.21 Finally, a single study found that neither microinfarcts nor larger
infarcts were associated with dementia when controlling for each other.27 The
preponderance of the evidence therefore suggests that while both microinfarcts and lacunar
infarcts may increase the risk of dementia, it is the smaller but more numerous microinfarcts
that may be the relatively stronger contributor. More, larger studies with careful pathological
assessment are needed to clarify the clinical relevance of microinfarcts compared to the
entire spectrum of abnormalities due to small vessel disease, including white matter lesions,
microbleeds and ischemic lesions.
There are few data on the prevalence of microinfarcts in persons with mild cognitive
impairment (MCI) rather than dementia. One study found an intermediate prevalence of
microinfarcts in persons with CDR greater than 0 but no dementia (26/47, 44%) compared to
persons who were cognitively normal (25/88, 28%) or demented (47/74, 64%),8 while
another study found no differences between cognitively normal and MCI (normal: 41/170,
24%; MCI 28/134, 20.9%; AD dementia 57/179, 31.8%).22
It is reasonable to surmise that the clinical impact of microinfarcts is determined by location
as well as number, but this aspect has not been extensively studied. Two studies suggest that
cortical microinfarcts may be more closely associated with dementia than subcortical
microinfarcts,19, 37 while another found that both cortical and basal ganglia or thalamic
infarcts independently contributed to likelihood of dementia.11
The relationship between microinfarcts and neuropsychological test performance has been
investigated in a prospective community-based autopsy study.19 Microinfarcts were
associated with episodic memory, semantic memory and visual perceptual speed, but not
working memory or visuospatial function, in models controlling for age, sex, education,
macroinfarcts, AD pathology and Lewy bodies.19 Cortical microinfarcts but not subcortical
microinfarcts were associated with poor cognitive performance.19 Microinfarcts were
associated with age-related cognitive decline but not the more rapid terminal cognitive
decline preceding death.83
There is limited information on the relationship between microinfarcts and clinical findings
other than cognitive dysfunction. Gait impairment has been linked to microinfarcts in a
small number of cases,69, 84 and a large community-based autopsy study showed that
multiple microinfarcts were associated with Parkinsonism after controlling for macroinfarcts
and other neuropathologies.85 Microinfarcts are more prevalent in patients with Parkinson’s
disease or Lewy body disease compared to healthy controls.86 Reports on associations with
depression are inconsistent. Two studies from the same group failed to find an association
between microinfarcts and depression87 or post-stroke depression,88 while another smaller
study of patients with vascular dementia or Alzheimer’s dementia did find an association
with depression.70
AREAS FOR FUTURE INVESTIGATION
There are many important directions for future studies that could move the field in the
direction of new treatment approaches for preventing microinfarct-related neurologic
dysfunction. Some salient possibilities are listed below.
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Develop standardized neuropathologic methods
A standardized approach to the detection, diagnosis, and classification of microinfarcts
would allow valid comparisons across populations and research groups, and potentially
provide clues to microinfarct pathophysiology. Therefore, development of new consensus
standards should be a priority. The standardized method would need to include specific
guidelines on which brain regions should be sampled, how tissue should be stained, and how
identified lesions should be classified. General guidelines provided by the NINDS – CSN
VCI Harmonization Standards6 provide a reasonable starting point for standard blocking
protocols (to include the traditional CERAD regions24 plus sections of the anterior and
posterior white matter43, 71, 86); in addition we suggest that basal ganglia, thalamus, pons,
cerebellum, occipital cortex, periventricular, arterial borderzone25–27 and motor regions27
should be sampled as well. Microinfarct load in both cortical and subcortical brain regions
should be recorded. With regard to staining methods, H&E appears to be a good technique
for identifying microinfarcts, but with unclear sensitivity and specificity relative to
immunohistochemical methods. Given that non-infarct pathologies may result in the
clustering of reactive astrocytes or microglia, one may hypothesize that
immunohistochemical markers for inflammation or injury may increase sensitivity but
decrease specificity for microinfarct detection, suggesting they should be used as an
adjunctive but not primary measure at present. Finally, the major outstanding question for
microinfarct classification is how to categorize milder injuries without clear cavitation,
including the distinct foci of tissue pallor or gliosis that can occur with small vessel disease.
Though sometimes referred to as incomplete ischemic injury or subinfarctive injury, there
are no detailed standardized definitions or gradations of these injuries, and their relationship
with complete microinfarcts is not well established. In the absence of a better understanding
of the relationship between “complete” and “incomplete” lesions, it seems reasonable to
record and analyze the two lesions individually. Data collection should also include the
presumed age of the microinfarct, since established or cavitated microinfarcts might be
better correlates of clinical status than recent microinfarcts representing perimortem rather
than ante-mortem events. However, by analogy with lacunar lesions, we should not assume
that microinfarcts all cavitate or that those that cavitate do so at the same rate.60 Finally,
total counts of microinfarcts should be collected and reported along with the sampling
strategy employed, to determine the total burden of microinfarct pathology.
Collect data on pathologies and risk factors associated with microinfarcts
Despite the emerging impression that these lesions reflect infarction related to advanced
small vessel disease, the precise pathogenesis of microinfarcts is not known. It will thus be
important to establish which pathologies, risk factors and medical conditions are associated
with microinfarcts in different populations. Potential mechanisms for microinfarction
include occlusive vascular disease, embolism, hypoperfusion, and disruptions to the blood
brain barrier. Focal injury related to oxidative stress, inflammation or other mechanisms are
also possible. Indeed, the pathogenesis of microinfarcts may be the result of more than one
mechanism. Unraveling these potential mechanisms could be best accomplished by clinical-
imaging correlation studies using an accurate, noninvasive method for microinfarct detection
during life (see below). In the absence of such an imaging modality, detailed prospective
clinical-pathological correlation studies that collect extensive information on associated
clinical risk factors and vascular pathologies remain the most compelling approach.
Determine the full anatomic extent and physiologic impact of microinfarcts
It will be important to establish the mechanisms by which these very small foci of tissue
injury result in impaired neurologic function. As noted above, the finding of even a few
microinfarcts in a small volume of sampled brain tissue implies a large global burden of
microinfarcts and volume of tissue loss; working this out with precision will require more
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detailed information on variations in microinfarct density across various brain regions. An
intriguing potential approach to this question is post mortem MRI at high field strength and
spatial resolution, which offers the theoretical possibility of imaging microinfarcts
throughout the entire brain.89 There may also be related tissue injuries extending beyond the
immediate microinfarct focus. These distant injuries could include regional oxidative stress,
inflammation or other tissue changes. Alternatively, microinfarcts may be a surrogate
marker of other pathophysiologic disruptions such as disruptions in the blood brain barrier
or generalized hypoperfusion. Future studies are needed to estimate microinfarct load,
related tissue injuries, and the potential roles of inflammation, oxidative stress or blood brain
barrier disruptions in promoting brain dysfunction.
Identify noninvasive methods for detection of microinfarcts in life
Establishing accurate means of identifying microinfarcts during life would represent perhaps
the greatest step towards elucidating the causes and effects of these lesions. Enhanced
detection on MRI could be enabled by higher field strengths51, 90 and higher spatial
resolution, although trade-offs in increased scan acquisition time may make current research
approaches challenging for even the most cooperative patients.
Given the technical challenges in identifying individual microinfarcts, a potentially fruitful
alternative approach is to infer their presence by identifying patterns of associated lesions.
MRI-defined cerebral small vessel disease is associated with increased vascular permeability
on MRI,91 and retinal microvascular abnormalities,92, 93 but it is not currently known
whether these abnormalities are also specifically associated with microinfarction. Other
consequences of microinfarction could include regional or global brain atrophy, or subtle
alterations in white matter water proton diffusivity or fractional anisotropy detectable using
diffusion-tensor imaging.94 Some small MRI lesions currently considered to be enlarged
perivascular spaces might actually represent visible microinfarcts.
Incorporate incident microinfarcts as a neuroimaging marker in clinical studies and trials
Current MRI DWI sequences, though limited in spatial and temporal resolution, offer a
convenient and readily available method for detecting at least some incident acute
microinfarcts in individuals undergoing MRI in observational or interventional studies. New
microinfarcts, if at the larger end of the spectrum (greater than 1 mm), may remain visible as
focal hyperintensities on T2-weighted images or lesions with signal characteristics similar to
enlarged perivascular spaces. Incident microinfarcts, and possibly incident enlarged
perivascular space-like lesions, could thus reasonably be incorporated as ancillary markers
in studies aimed at preventing progression of small vessel brain disease. This possibility is
particularly attractive for vascular conditions such as hypertensive brain disease or advanced
CAA,61 in which the incidence of these lesions may be high enough to allow a treatment-
related reduction to be detectable. An important goal for future investigations in this area
will be to collect more data on the appearance, location, and associated risk factors for these
small, clinically silent DWI lesions, a promising noninvasive approach towards visualizing
the “invisible” microinfarct.
CONCLUSIONS
Despite the large number of unanswered questions about cerebral microinfarcts, it is
possible to make some preliminary conclusions. Microinfarcts are quite numerous in the
aged brain, particularly in individuals with cognitive impairment or underlying small vessel
diseases. Nonetheless, they are difficult to detect directly and specifically during life based
on current neuroimaging capabilities. However, MRI DWI detects a surprisingly high
incidence of acute small infarctions in patients with symptomatic small vessel diseases,
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approaching the upper size limit of pathologically-defined microinfarcts. Mounting evidence
from clinical-autopsy correlation studies suggest that the numerous foci of tissue loss related
to cerebral microinfarcts may play a direct causal role in cognitive impairment, particularly
when present in combination with other age-related brain pathologies. Future work should
focus on achieving consensus pathological definitions, improving our understanding of the
pathogenesis and consequences to brain structure and function, and developing non-invasive
means of detection during life.
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Figure 1. Microinfarct pathology
A. Cystic (cavitated) microinfarct (diameter: 600 μm) in the basal ganglia; original
magnification 10x. B. Incomplete microinfarct without cavitation (diameter: 330 μm) in
midfrontal cortex; original magnification 10x. C. Cortical microinfarct with linear scarring
(“puckering”) from the middle temporal cortex (diameter 120 μm); original magnification
10x. D. Immunostatin for major histocompatibility complex II human leukocyte antigen
DR3 (MHCII HLA-DR3) expression in activated microglia and macrophages in a
microinfarct in the basal ganglia; original magnification 10X (diameter: 320 μm).
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Figure 2. Intra-cortical Small Infarcts Detected on Post-Mortem High-Field Strength MRI
Examples of pathologically-verified intracortical microinfarcts (white arrows) imaged on
post-mortem 7 tesla MRI (voxel size 0.3 mm3) of a 53 year old man who died of
CADASIL.51 Asterisks indicate linear hypointensities pathologically proven to be
perivascular spaces. The black bar indicates 1 mm. (Figure provided by E. Jouvent).
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Figure 3. MRI Diffusion-Weighted Imaging of Small Acute Infarction (Sample)
Example of small acute areas of restricted diffusion detected incidentally on MRI. Top
panels (A–C): A 70 year man with cerebral amyloid angiopathy who underwent MRI as part
of a research study. Hemosiderin staining from prior hemorrhages is seen on the T2*-
weighted gradient-recalled echo (GRE) sequence (A). Separate from these prior
hemorrhages, an asymptomatic small hyperintensity is seen in the right occipital cortex on
the diffusion-weighted image (DWI, panel B) with evidence of restricted diffusion on the
apparent diffusion coefficient sequence (ADC, panel C), consist with an acute small cortical
infarct. Bottom panels (D–F): A 67-year old man with an acute symptomatic lacunar infarct
in the right thalamus (D, DWI sequence) also demonstrates an asymptomatic small 4.5 mm
lesion in the right parietal white matter that is hyperintense on DWI (panel E) with restricted
diffusion on ADC (panel F). An asymptomatic simultaneous small vessel infarct was
suspected because no proximal source of embolism was identified and there was evidence of
coexisting chronic cerebral small vessel disease (note confluent white matter lesions
exhibiting increased diffusion in panel F).
Smith et al. Page 19
Lancet Neurol. Author manuscript; available in PMC 2013 March 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 4. Pooled Odds of Dementia in Persons with Microinfarcts (Unadjusted Analysis)
The unadjusted odds of dementia were more than doubled in the presence of microinfarcts
(odds ratio 2.31, 95% confidence interval 1.40 to 3.82). Significant heterogeneity in the odds
across studies (p=0.002) may be related to different methods for sampling for microinfarcts.
See the legend to Table 1 for an explanation of the study acronyms.
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